Chemos LLC Bulk Manufacturer DEA Application

Content

ACTION:

Notice of application.

SUMMARY:

Chemtos, LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION
listed below for further drug information.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on
or objections to the issuance of the proposed registration on or before May 29, 2026. Such persons may also file a written
request for a hearing on the application on or before May 29, 2026.

ADDRESSES:

The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file
for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive
a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit
the same comment.

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.33(a), this is notice that on February 13, 2026, Chemtos, LLC, 16713 Picadilly Court, Round
Rock, Texas 78664-8544, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
| --- | --- | --- |
| 4-Chloromethcathinone | 1239 | I |
| 1-(4-methoxyphenyl)-N-methylpropan-2-amine | 1245 | I |
| 4,4′-Dimethylaminorex | 1595 | I |
| 4F-MDMB-BINACA (4F-MDMB-BUTINACA or methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3- dimethylbutanoate) | 7043 | I |
| MDMB-4en-PINACA (methyl 3,3-dimethyl-2-(1-(pent-4- en-1-yl)-1H-indazole-3-carboxamido)butanoate) | 7090 | I |
| 2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine) | 7286 | I |
| Alpha-Pyrrolidinoheptaphenone (PV8) | 7548 | I |
| 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one | 7552 | I |
| Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) | 9751 | I |
| Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine) | 9756 | I |
| Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5- nitro-1H-benzimidazol-1-yl)ethan-1-amine) | 9757 | I |
| N-Pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1- (2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) | 9758 | I |
| Protonitazene (N,N-diethyl-2-(5-nitro-2-(4- propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine) | 9759 | I |
| 2-(4-Methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)- 1H-benzimidazole (N-pyrrolidino metonitazene) | 9762 | I |
| 5-Nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)- 1H-benzimidazole (N-pyrrolidino protonitazene) | 9763 | I |
| Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)- 1H-benzimidazol-1-yl)ethan-1-amine) | 9764 | I |
| Etodesnitazene; etazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) | 9765 | I |
| 2-(2-(Benzodioxol-5-ylmethyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine | 9766 | I |
| 2-(2-(4-Ethoxybenzyl)-5-methyl-1H-benzimidazol-1-yl)- N,N-diethylethan-1-amine | 9767 | I |
| 2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N-ethylethan-1-amine | 9768 | I |
| N-Ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine | 9769 | I |
| 2-(2-((2,3-Dihydrobenzofuran-5-yl)methyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine | 9770 | I |
| 2-(2-(4-Ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)- N,N-dimethylethan-1-amine | 9771 | I |
| 2-(4-Isopropoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1- yl)ethyl)-1H-benzimidazole | 9772 | I |
The company plan to bulk manufacture the listed controlled substances for distribution as reference standards to its customers.
No other activities for these drug codes are authorized for this registration.

Thomas Prevoznik, Deputy Assistant Administrator. [FR Doc. 2026-06052 Filed 3-27-26; 8:45 am] BILLING CODE P

Download File

Download